Affiliation:
1. The University of Tokyo
Abstract
Abstract
Objectives
In people with HIV, viremia is associated with chronic inflammation does not return to the level as in non-HIV-infected individuals even after viral suppression with antiretroviral therapy. The objective of this study was to determine whether long-acting cabotegravir plus rilpivirine has a different effect on reducing inflammation compared to oral antiretroviral drugs.
Design
In this retrospective cohort study, we followed the inflammation biomarkers, such as C-reactive protein and CD4/CD8 ratio, and lipid profiles from baseline to 7 months after starting injectable cabotegravir plus rilpivirine. Patients were grouped by the regimens prior to the switching.
Results
Seventy-eight patients were analyzed. Comparing baseline with 7 months after starting injectable cabotegravir plus rilpivirine, CD4/CD8 ratio and C-reactive protein did not change. CD8 count and CD4 count were significantly decreased in the group switching from dolutegravir-based regimen but not in the tenofovir alafenamide-based regimen group. High-density lipoprotein cholesterol increased resulting in the decrease in total-cholesterol/High-density lipoprotein cholesterol ratio, whereas there was no significant change in low-density lipoprotein cholesterol in all groups.
Conclusions
The change from oral antiretroviral therapy to long-acting cabotegravir plus rilpivirine did not change inflammatory biomarkers, but did improve some lipid profiles. No effect of tenofovir alafenamide on the lipid profile was observed.
Publisher
Research Square Platform LLC